Evidence map›Paper›PMID 41425430›Full record

ArticleAnnals of thoracic surgery short reports2025

Use of Andexanet Alfa to Reverse Heparin After Cardiopulmonary Bypass.

David Niehaus, Michael Javorski, Elliot Kay, Abigail Rhoades, Hilary Raidt, Rob Dowling

Abstract readCase Reports
In one paragraph

Article in Annals of thoracic surgery short reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

David NiehausThe Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, Cincinnati, Ohio.
Michael JavorskiCardiothoracic Surgery Department, Heart and Vascular Institute, The Christ Hospital, Cincinnati, Ohio.
Elliot KayAnesthesia Associates of Cincinnati, Cincinnati, Ohio.
Abigail RhoadesPharmaceutical Department at The Christ Hospital, Cincinnati, Ohio.
Hilary RaidtPharmaceutical Department at The Christ Hospital, Cincinnati, Ohio.
Rob DowlingCardiothoracic Surgery Department, Heart and Vascular Institute, The Christ Hospital, Cincinnati, Ohio.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heparin is the primary anticoagulant used for cardiopulmonary bypass and requires reversal to prevent postoperative bleeding. Protamine sulfate is the only United States Food and Drug Administration-approved heparin reversal agent and therefore is routinely used after cardiopulmonary bypass. Severe intraoperative protamine reactions are infrequent but may preclude full heparin reversal. Andexanet alfa has demonstrated effective in vitro heparin reversal, but clinical use has not been reported. We review the preclinical data on andexanet alfa as a heparin reversal agent and report a clinical case of andexanet alfa infusion, with complete laboratory and clinical evidence of heparin reversal.

Identifiers

PMID41425430
PMCPMC12712153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.